Project Grant HT94252510848
Award Date
10/1/25
Completion Date
9/30/28
Dollars Obligated
$1.6M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21218, USA
Similar Awards
The Johns Hopkins University was awarded a $734,296 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will support research titled "PRETARGETING BACTERIAL THERAPY OF HER2+ BREAST CANCER" from June 1, 2023 through May 31, 2026. This award will fund applied biomedical studies at Johns Hopkins aimed at investigating medical solutions for breast cancer treatment through pretargeting bacterial...
The Johns Hopkins University was awarded a $493,829 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will support research titled "PRETARGETING BACTERIAL THERAPY OF HER2+ BREAST CANCER" from June 1, 2023 through May 31, 2026. Through this award, The Johns Hopkins University will conduct applied biomedical studies to investigate medical solutions for breast cancer on the battlefield....
The Johns Hopkins University received a three-year, $651,158 Project Grant award from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will support the university's research into early assessment of treatment response in breast cancer patients undergoing neoadjuvant therapy using an automated liquid biopsy-breast cancer methylation assay. The Military Medical Research and Development program aims to transform military...
This $1,473,751 federal Project Grant award, issued on August 15, 2024 by the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420), supports research by The Johns Hopkins University to investigate the influence of the tumor immune microenvironment and microbiome on prostate cancer immunotherapy response in Black men. The 3-year research initiative aims to transform healthcare through innovative and impactful medical research focused...
This $1,637,500 federal Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research conducted by The Johns Hopkins University to target specific PARP1 inhibition for breast cancer treatment. The award, which began on July 1, 2024 and will be completed by June 30, 2027, will enable the university to conduct innovative scientific studies ranging from basic laboratory research to advanced clinical trials focused on improving...
This $1,473,750 federal Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports The Johns Hopkins University's research study on "The Immunomodulatory Impact of Chemotherapy When Combined with PD-1 Blockade in Resectable Lung Cancer." The 3-year grant, running from September 1, 2024 to August 31, 2027, aims to investigate innovative immunological interventions for treating lung cancer in military service...
The Department of Defense's Defense Health Agency awarded a $465,750 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to The Johns Hopkins University. The grant, titled "ESTROGEN RECEPTOR MUTATIONS AS A NOVEL BIOMARKER FOR RESPONSE TO ENDOCRINE THERAPY IN OVARIAN CANCER," will fund research to investigate estrogen receptor mutations as a potential biomarker for improved response to endocrine therapy in ovarian cancer patients. The grant period...
The Department of Defense's Defense Health Agency awarded a $318,483 Project Grant to The Johns Hopkins University under the Military Medical Research and Development (CFDA 12.420) program. The grant supports advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader public. Specifically, the funding will be used for a 2-year project to quantitatively measure acute and chronic lesion activity in a real-world, multi-site clinical MRI...
The Department of Defense's Defense Health Agency awarded a $232,878 Project Grant to The Johns Hopkins University to conduct research on "EXPLORING THE ROLE OF EPITRANSCRIPTOMICS IN THE EVOLUTION OF NEUROENDOCRINE PROSTATE CANCER." This grant is funded through the Military Medical Research and Development (CFDA 12.420) program, which supports advanced biomedical research to transform healthcare for military service members, veterans, and the public. The research will be conducted from...
This federal Project Grant award, ID HT94252410076, was provided by the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420) to The Johns Hopkins University. The $163,750 award, granted on February 1, 2024, will support research examining the influence of the gut microbiome on drug metabolism and treatment resistance in prostate cancer, with a completion date of January 31, 2026. As a leading research institution, The Johns Hopkins...